Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

[1]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[2]  Haider Mahdi,et al.  Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011. , 2016, Gynecologic oncology.

[3]  R. Alvarez,et al.  Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation. , 2016, JAMA oncology.

[4]  J. Cuzick,et al.  Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial , 2016, The Lancet.

[5]  Kenneth Offit,et al.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  B. Mol,et al.  Surgical approach to hysterectomy for benign gynaecological disease. , 2015, The Cochrane database of systematic reviews.

[7]  J. Manson,et al.  Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. , 2015, JAMA oncology.

[8]  B. Karlan,et al.  Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[10]  D. Easton,et al.  Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations , 2013, Journal of Medical Genetics.

[11]  S. Lejeune,et al.  Hystérectomie prophylactique : quelle indication ? , 2013 .

[12]  J. Bakkum-Gamez,et al.  Challenging and complex decisions in the management of the BRCA mutation carrier. , 2013, Journal of women's health.

[13]  B. Karlan,et al.  The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. , 2013, Gynecologic oncology.

[14]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[15]  Richard G. Moore,et al.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. , 2013, Gynecologic oncology.

[16]  T. Tulandi,et al.  Abdominal versus laparoscopic hysterectomies for benign diseases: evaluation of morbidity and mortality among 465,798 cases , 2013, Gynecological Surgery.

[17]  H. Hollema,et al.  Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers , 2012, Modern Pathology.

[18]  M. Greene,et al.  New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research. , 2012, Gynecologic oncology.

[19]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[20]  S. Gruber,et al.  Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[22]  L. Dubeau,et al.  The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.

[23]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Chlebowski,et al.  National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. , 2007, Clinical breast cancer.

[26]  M. Piver,et al.  Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. , 2006, Gynecologic oncology.

[27]  R. Barakat,et al.  Comparison of uterine malignancies that develop during and following tamoxifen therapy. , 2006, Gynecologic oncology.

[28]  John L Hopper,et al.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.

[29]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[30]  J. Satagopan,et al.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[32]  H. Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[33]  R. Osborne,et al.  kConFab: a research resource of Australasian breast cancer families , 2000, The Medical journal of Australia.

[34]  Jama Oncology.  Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations , 2016 .

[35]  Herbert Waldmann,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA 1 and BRCA 2 , 2015 .

[36]  S. Lejeune,et al.  [Indications for prophylactic hysterectomy]. , 2013, Gynécologie Obstétrique & Fertilité.

[37]  S. Miller,et al.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2012 .

[38]  A. Berchuck,et al.  Relationship between tamoxifen use and high risk endometrial cancer histologic types. , 2009, Gynecologic oncology.

[39]  ACOG Committee Opinion No. 444: choosing the route of hysterectomy for benign disease. , 2009, Obstetrics and gynecology.

[40]  J. Hopper,et al.  Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort , 2004, Familial Cancer.

[41]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.